Senators crank up volume on demand for medical device identifier

Capital Building - 22.21 Kb
From a bipartisan duo in the Senate comes a 244-page bill with language calling on the U.S. Department of the Health and Human Services (HHS) to put forth a final unique medical device identifier (UDI) rule sooner rather than later.

Sponsored by Iowa Democrat Tom Harkin and Wyoming Republican Michael Enzi, the FDA's Safety and Innovation Act would amend existing law by, in part, calling for the department to make the rule that will establish the UDI system by no later than Dec. 31.

This is followed by a clause stating, “The Secretary shall implement the unique device identification system under this subsection as soon as practicable.”

The UDI rule would mandate a tag on all medical devices so they can be tracked throughout their lifecycle in the healthcare system, facilitating quicker responses to problem devices, including implantables.

In March, a bipartisan Senate foursome introduced a bill, the Ensuring Safe Medical Devices for Patients Act, likewise calling for a UDI rule by the end of this year while also adding medical devices to the FDA’s Sentinel postmarket surveillance initiative.

Congress approved a UDI system five years ago as part of the FDA Amendments Act of 2007, but the initiative has been slow to gain traction. In February, a bipartisan Senate trio wrote the acting director of the Office of Management and Budget to demand a status report and a plan—a reaction to the office missing an important UDI deadline last October.

The new bill also addresses user-fee programs and other issues involving prescription drugs.

Harkin and Enzi are, respectively, the chairman and ranking member of the Senate’s Health, Education, Labor & Pensions Committee. They have scheduled an executive session to discuss the new legislation April 25.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.